FOOTHILL RANCH, Calif.,
Aug. 16, 2021 /PRNewswire/
-- Demonstrating a deep commitment to expanding the core
capabilities and diversity of its Board of Directors, BIOLASE,
Inc. (NASDAQ: BIOL), the global leader in dental
lasers, today announced it has appointed three new board
members to its Board of Directors (the "Board"), effective
immediately. Drs. Kathleen T.
O'Loughlin, Carol Gomez
Summerhays, and Martha
Somerman join a Board that has been instrumental in
establishing and implementing the Company's business plan, which
has demonstrated significant growth over the past several
quarters.
"As we embark on an aggressive growth strategy, I am pleased to
welcome the new Board members as their extensive experience in
dental practice, translational and clinical research, and dental
education will be extremely helpful as we continue to execute on
the BIOLASE business plan," commented Jonathan T. Lord, M.D., Chairman of the Board of
BIOLASE. "We are delighted to have each of these women join our
board and look forward to their contributions as we continue to
execute on our plan for long-term growth."
The new Board members are proven leaders and will enable the
Company to achieve its growth prospects:
- Dr. Kathleen T. O'Loughlin is
currently the Executive Director of the American Dental Association
and is retiring from the American Dental Association by the end of
this year. Previously, Dr. O'Loughlin served as Chief Dental
Officer of United Health Group, and from 2002 to 2008 she served as
President and Chief Executive Officer of Delta Dental of
Massachusetts. Dr. O'Loughlin
serves on the Board of Directors of the American Dental Association
and previously served as a Trustee at Tufts
University. Dr. O'Loughlin received her Masters in Public
Health from Harvard University, a
Doctor of Dental Medicine, Summa Cum Laude, from Tufts University, and a B.A from Boston University.
- Dr. Carol Gomez Summerhays is
currently the Chair of the Board of Councilors of the University of Southern California Ostrow School of
Dentistry and is a former President of the American Dental
Association and President of the California Dental Association. Dr.
Summerhays worked in private dental practice from 1982-2015. Dr.
Summerhays served in the United
States Navy Dental Corps from 1974 to 1989. Dr. Summerhays
received her Doctor of Dental Surgery from University of Southern California, and B.S. from
University of San Francisco.
- Dr. Martha Somerman is the Chief
Field Editor of Frontiers in Dental Medicine. She was the Director,
National Institute of Dental and Craniofacial Research, National
Institutes of Health (NIH) from August
2011 to December 2019 and then
served as a senior advisor for NIDCR until her retirement on
May 31, 2021. In addition, she was
the Principal Investigator for the Laboratory of Oral Connective
Tissue Biology, National Institute of Arthritis and Musculoskeletal
and Skin Diseases, NIH, from August
2011 to May 31, 2021. Her
laboratory team focused on identifying factors controlling the
development of the periodontal complex and applying this knowledge
toward developing strategies to regenerate periodontal tissue lost
as a consequence of disease. Prior to becoming NIDCR director, Dr.
Somerman was Dean of the University of
Washington School of Dentistry, a position she held since
2002. From 1991 to 2002, Dr. Somerman was on the faculty of the
University of Michigan School of
Dentistry where she served as a professor and chair of
periodontics/prevention and geriatrics. From 1984 to 1991, Dr.
Somerman was on the faculty of the University
of Maryland College of Dental Surgery. Dr. Somerman received
a bachelor's degree in biology and a D.D.S. from New York University, a Masters in Environmental
Health from Hunter College, and a Ph.D.
in Pharmacology from the University of
Rochester. She completed her periodontal residency at the
Eastman Dental Center in Rochester, New
York and is a diplomat of the American Board of
Periodontology.
In conjunction with the new appointments, Dr. Michael DiTolla and Garrett Sato (retirement) resigned as members of
the Board to pursue other interests. The appointments increase the
size of the BIOLASE Board to nine members.
About BIOLASE
BIOLASE is a medical device company that develops,
manufactures, markets, and sells laser systems in dentistry and
medicine. BIOLASE's products advance the practice of dentistry and
medicine for patients and healthcare professionals. BIOLASE's
proprietary laser products incorporate approximately 271 patented
and 40 patent-pending technologies designed to provide biologically
and clinically superior performance with less pain and faster
recovery times. BIOLASE's innovative products provide cutting-edge
technology at competitive prices to deliver superior results for
dentists and patients. BIOLASE's principal products are
revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical
applications. BIOLASE has sold over 41,200 laser systems
to date in over 80 countries around the world. Laser products under
development address BIOLASE's core dental market and other adjacent
medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase
Express™, and laser dentistry, find BIOLASE online
at www.biolase.com, Facebook at www.facebook.com/biolase,
Twitter at www.twitter.com/biolaseinc, Instagram
at www.instagram.com/waterlase_laserdentistry, and LinkedIn
at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered
trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that
term is defined in the Private Litigation Reform Act of 1995, that
involve significant risks and uncertainties, including statements
regarding the anticipated roll out of new go-to-market sales
strategies, the Company's efforts to achieve its goal of becoming
EBITDA positive. Forward-looking statements can be identified
through the use of words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," "may,"
"will," "should," and variations of these words or similar
expressions. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect BIOLASE's current
expectations and speak only as of the date of this release. Actual
results may differ materially from BIOLASE's current expectations
depending upon a number of factors. These factors include,
among others, adverse changes in general economic and market
conditions, competitive factors including but not limited to
pricing pressures and new product introductions, uncertainty of
customer acceptance of new product offerings and market changes,
risks associated with managing the growth of the business, and
those other risks and uncertainties that are described, from
time-to-time, in the "Risk Factors" section of BIOLASE's annual
reports filed on Form 10-K with the Securities and Exchange
Commission. Except as required by law, BIOLASE does not undertake
any responsibility to revise or update any forward-looking
statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolase-expands-core-capabilities-as-it-appoints-three-new-board-members-with-significant-dental-experience-301355483.html
SOURCE BIOLASE, Inc.